AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32833851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 36087699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (SEKT)
Number of subjects: 59
Study 36087699 — intervention group
Group type: COMPARATOR
Intervention: Emotion-focused intervention (FEST)
Number of subjects: 59
Study 33206059 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended care with telerehabilitation (including a weekly group teleconference session)
Number of subjects: 36
Study 33206059 — intervention group
Group type: COMPARATOR
Intervention: Recommended care (internet-delivered evidence-based exercise and education)
Number of subjects: 36
Study 33206059 — intervention group
Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 36
Study 36129233 — intervention group
Group type: EXPERIMENTAL
Intervention: RHA-M (hyaluronic acid fillers with mepivacaine)
Number of subjects: 30
Study 36129233 — intervention group
Group type: COMPARATOR
Intervention: RHA (hyaluronic acid fillers with lidocaine)
Number of subjects: 30
Study 36129233 — intervention group
Group type: EXPERIMENTAL
Intervention: RHA-M
Number of subjects: 30
Study 36129233 — intervention group
Group type: COMPARATOR
Intervention: RHA
Number of subjects: 30
Study 36129233 — intervention group
Group type: EXPERIMENTAL
Intervention: RHA-M and RHA
Number of subjects: 30
Study 32488263 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC 25/25
Number of subjects: 829
Study 32488263 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC 50/50
Number of subjects: 829
Study 32488263 — intervention group
Group type: COMPARATOR
Intervention: D50
Number of subjects: 829
Study 32488263 — intervention group
Group type: COMPARATOR
Intervention: T50
Number of subjects: 829
Study 32980384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 693
Study 32980384 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional conformal radiotherapy (3D-CRT)
Number of subjects: 693
Study 33261578 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy (AAT) with a bird for eight weeks
Number of subjects: 70
Study 33261578 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 33261578 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy (AAT)
Number of subjects: 70
Study 35613759 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Binocular Viewing (BBV)
Number of subjects: 44
Study 35613759 — intervention group
Group type: COMPARATOR
Intervention: Standard occlusion/atropine blurring
Number of subjects: 44
Study 33710921 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-axis out-of-plane technique
Number of subjects: 80
Study 33710921 — intervention group
Group type: COMPARATOR
Intervention: Long-axis in-plane technique
Number of subjects: 80
Study 33710921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study 34462262 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline local joint swelling
Number of subjects: 508
Study 33765904 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain synbiotic (n=54)
Number of subjects: 87
Study 33765904 — intervention group
Group type: COMPARATOR
Intervention: Simethicone (n=33)
Number of subjects: 87
Study 32624377 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine patch (10 μg/h)
Number of subjects: 160
Study 32624377 — intervention group
Group type: COMPARATOR
Intervention: Oral celecoxib
Number of subjects: 160
Study 36103665 — intervention group
Group type: EXPERIMENTAL
Intervention: Restylane Lyft (1 ml on day 1, re-treatment of 0.5 ml at month 12)
Number of subjects: 132
Study 36103665 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (1 ml offered at month 6)
Number of subjects: 132
Study 33798509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose gel (200 mg/kg)
Number of subjects: 133
Study 33798509 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dose of dextrose gel
Number of subjects: 133
Study 33798509 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 133
Study 32379673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheetali pranayama (intervention group, n = 50)
Number of subjects: 100
Study 32379673 — intervention group
Group type: COMPARATOR
Intervention: HTN without pranayama (control group, n = 50)
Number of subjects: 100
Study 35144326 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual + Rhemercise (n=63)
Number of subjects: 126
Study 35144326 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only (n=63)
Number of subjects: 126
Study 34874419 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy through a nasal cannula
Number of subjects: 220
Study 34874419 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 220
Study 33957377 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified maximum transverse diameter approach
Number of subjects: 536
Study 33957377 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans interpreted by six volunteer radiologists
Number of subjects: 536
Study 33957377 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLungCa-500 dataset markup
Number of subjects: 536
Study 33957377 — intervention group
Group type: EXPERIMENTAL
Intervention: Markup process duration
Number of subjects: 536
Study 36752479 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (home and supervised aerobic exercise over 6 months)
Number of subjects: 120
Study 36752479 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 120
Study 36752479 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 120
Study 33642340 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Vitamin C
Number of subjects: 24
Study 32580979 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Readiness and Appropriateness Measure (TRAM)
Number of subjects: 1000
Study 34518950 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled transection (Endo GIA Reinforced Reload with Tri‐Staple Technology)
Number of subjects: 145
Study 34518950 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic transection (Harmonic Focus + or Harmonic Ace + shears)
Number of subjects: 145
Study 34518950 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled transection
Number of subjects: 145
Study 34518950 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic transection
Number of subjects: 145
Study 34518950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study 33351209 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB microphototherapy 300 to 320 nm (Bioskin©) 1 x week
Number of subjects: 40
Study 33351209 — intervention group
Group type: EXPERIMENTAL
Intervention: VITILSI© gel 2 x day
Number of subjects: 40
Study 33351209 — intervention group
Group type: EXPERIMENTAL
Intervention: VITILSI© gel 2 x day + Bioskin© 1 x week
Number of subjects: 40
Study 33351209 — intervention group
Group type: COMPARATOR
Intervention: Placebo 2 x day
Number of subjects: 40
Study 35302901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative injection of autologous microfragmented adipose tissue
Number of subjects: 44
Study 35302901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection of autologous microfragmented adipose tissue)
Number of subjects: 44
Study 34695399 — intervention group
Group type: EXPERIMENTAL
Intervention: En face optical coherence tomography (OCT) assessment of ellipsoid zone (EZ) recovery
Number of subjects: 61
Study 34695399 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in hyporeflective area
Number of subjects: 61
Study 34695399 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of macula-off
Number of subjects: 61
Study 33221969 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + nintedanib
Number of subjects: 24
Study 33221969 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy + placebo
Number of subjects: 24
Study 32696120 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on infant crying and the dangers of shaking and smothering
Number of subjects: 4722
Study 32696120 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 4722
Study 33632249 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFire assay
Number of subjects: 0
Study 33632249 — intervention group
Group type: EXPERIMENTAL
Intervention: QuickVue rapid test
Number of subjects: 0
Study 33632249 — intervention group
Group type: COMPARATOR
Intervention: qPCR
Number of subjects: 0
Study 32384478 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 combined with XiangShaLiuJunZi decoction (XSLJZD)
Number of subjects: 0
Study 32384478 — intervention group
Group type: COMPARATOR
Intervention: S‐1
Number of subjects: 0
Study 32535646 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravenous adrenaline
Number of subjects: 8016
Study 32535646 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8016
Study 32535646 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 8016
Study 33597283 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist access during crisis management
Number of subjects: 138
Study 33597283 — intervention group
Group type: COMPARATOR
Intervention: No checklist access during crisis management
Number of subjects: 138
Study 32698123 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lactalbumin (LA) 40 g
Number of subjects: 12
Study 32698123 — intervention group
Group type: COMPARATOR
Intervention: Collagen peptide (CP) 40 g
Number of subjects: 12
Study 35439293 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus bendamustine (R-B)
Number of subjects: 329
Study 35439293 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP/R-DHAP
Number of subjects: 329
Study 33150389 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (n = 54)
Number of subjects: 103
Study 33150389 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 49)
Number of subjects: 103
Study 32707605 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a plus adefovir dipivoxil (ADV)
Number of subjects: 60
Study 32707605 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a alone
Number of subjects: 60
Study 32707605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil alone
Number of subjects: 60
Study 32707605 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a (retreatment)
Number of subjects: 60
Study 32707605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (retreatment)
Number of subjects: 60
Study 32707605 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis
Number of subjects: 60
Study 32707605 — intervention group
Group type: COMPARATOR
Intervention: Noncirrhotic
Number of subjects: 60
Study 35613989 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 80
Study 35613989 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 80
Study 34739196 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 3872
Study 34739196 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 3872
Study 35847015 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinhuapinggan granules (YHPG)
Number of subjects: 240
Study 35847015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 33317139 — intervention group
Group type: EXPERIMENTAL
Intervention: Preworkout multi-ingredient (PREW)
Number of subjects: 14
Study 33317139 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO)
Number of subjects: 14
Study 35182721 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg i.v. on day 1 with neoadjuvant carboplatin and nab-paclitaxel
Number of subjects: 280
Study 35182721 — intervention group
Group type: COMPARATOR
Intervention: No atezolizumab with neoadjuvant carboplatin and nab-paclitaxel
Number of subjects: 280
Study 34295720 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (listening to preferred music during the procedure)
Number of subjects: 91
Study 34295720 — intervention group
Group type: COMPARATOR
Intervention: Non-music group (no music during the procedure)
Number of subjects: 91
Study 37246680 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training (Intensity 80-90% of target heart rate) for 8 weeks
Number of subjects: 42
Study 37246680 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity aerobic training (Intensity 40-60% of target heart rate)
Number of subjects: 42
Study 35331959 — intervention group
Group type: EXPERIMENTAL
Intervention: NSPT + PDT
Number of subjects: 46
Study 35331959 — intervention group
Group type: COMPARATOR
Intervention: NSPT
Number of subjects: 46
Study 32861716 — intervention group
Group type: EXPERIMENTAL
Intervention: C2238 ANP allele (homozygous CC)
Number of subjects: 557
Study 32861716 — intervention group
Group type: COMPARATOR
Intervention: TT wild type genotype
Number of subjects: 557
Study 32505198 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate estimators
Number of subjects: 714
Study 32505198 — intervention group
Group type: EXPERIMENTAL
Intervention: Male under-estimators
Number of subjects: 714
Study 32505198 — intervention group
Group type: EXPERIMENTAL
Intervention: Inaccurate perception groups (male)
Number of subjects: 714
Study 32505198 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help score (women)
Number of subjects: 714
Study 32505198 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help score (men)
Number of subjects: 714
Study 32505198 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help behaviours
Number of subjects: 714
Study 34585595 — intervention group
Group type: EXPERIMENTAL
Intervention: loteprednol‐etabonate 0.5% twice daily for 14 days tapered to once daily for 14 days, and then twice weekly for 28 days
Number of subjects: 10
Study 34585595 — intervention group
Group type: EXPERIMENTAL
Intervention: loteprednol‐etabonate 0.5%
Number of subjects: 10
Study 34585595 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 10
Study 32722454 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% carbohydrate (CHO) solution (5 mL/kg/bw)
Number of subjects: 15
Study 32722454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) solution (flavour and appearance-matched, 5 mL/kg/bw)
Number of subjects: 15
Study 32722454 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO ingestion
Number of subjects: 15
Study 36476442 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISP method with flipped classroom approach
Number of subjects: 120
Study 36476442 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based learning method
Number of subjects: 120
Study 34462574 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) for schizophrenia
Number of subjects: 29878
Study 34462574 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic NDI
Number of subjects: 29878
Study 32457004 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity aerobic exercise training (50-80% of maximal heart rate), 15-45 min/day, 3 days a week for 6 weeks
Number of subjects: 22
Study 32457004 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity aerobic exercise training
Number of subjects: 22
Study 32457004 — intervention group
Group type: COMPARATOR
Intervention: Control group (alternating active upper extremity exercises for the same period)
Number of subjects: 22
Study 35033117 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Computer‐Assisted Self Interviewing (ACASI) combined with face‐to‐face interviews
Number of subjects: 0
Study 35033117 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face interviews
Number of subjects: 0
Study 89012353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin and vaccine on schedule
Number of subjects: 3464
Study 89012353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin and vaccine off schedule
Number of subjects: 3464
Study 89012353 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (overall population)
Number of subjects: 3464
Study 34699967 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol/budesonide (180/160 µg)
Number of subjects: 60
Study 34699967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34699967 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol/budesonide
Number of subjects: 60
Study 32562651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-married rate for those aged 15–19 years
Number of subjects: 0
Study 32562651 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific fertility rate (ASFR) for those aged 15–19 years
Number of subjects: 0
Study 32562651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-married rate for women aged 20–24 years
Number of subjects: 0
Study 32562651 — intervention group
Group type: EXPERIMENTAL
Intervention: ASFR for women aged 20–24 years
Number of subjects: 0
Study 32562651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-married rate for girls and women in rural areas aged 15–19 years
Number of subjects: 0
Study 32562651 — intervention group
Group type: EXPERIMENTAL
Intervention: ASFR for girls and women in rural areas aged 15–19 years
Number of subjects: 0
Study 32562651 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level impact on ever-married rate
Number of subjects: 0
Study 32562651 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic disparities in marriage and childbearing
Number of subjects: 0
Study 32562651 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective association of education against adolescent childbearing
Number of subjects: 0
Study 32562651 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for adolescent marriage and childbearing
Number of subjects: 0
Study 35786028 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made functional foot orthoses
Number of subjects: 66
Study 35786028 — intervention group
Group type: COMPARATOR
Intervention: Flat cushioning insoles
Number of subjects: 66
Study 34397827 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia (IH)
Number of subjects: 104
Study 34397827 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 104
Study 37665297 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib + binimetinib
Number of subjects: 0
Study 37665297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34570180 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg, twice daily)
Number of subjects: 200
Study 34570180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 32197128 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory stimulation on below-level insensate body regions
Number of subjects: 11
Study 33940082 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sleep restriction (SR; 2 hr sleep opportunity/night)
Number of subjects: 18
Study 33940082 — intervention group
Group type: COMPARATOR
Intervention: Adequate sleep (AS; 7–9 hr sleep opportunity/night)
Number of subjects: 18
Study 33940082 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sleep restriction (SR)
Number of subjects: 18
Study 33940082 — intervention group
Group type: COMPARATOR
Intervention: Adequate sleep (AS)
Number of subjects: 18
Study 32175680 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of edaravone with taurine
Number of subjects: 0
Study 32175680 — intervention group
Group type: COMPARATOR
Intervention: Taurine
Number of subjects: 0
Study 35371949 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with muscle training (MT) of the postpartum pelvic floor
Number of subjects: 92
Study 35371949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehabilitation)
Number of subjects: 92
Study 33562090 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented powdered soy product (12.5 g each, 2 packets daily)
Number of subjects: 27
Study 33562090 — intervention group
Group type: COMPARATOR
Intervention: Germinated brown rice control powder (isoenergic)
Number of subjects: 27
Study 34100215 — intervention group
Group type: EXPERIMENTAL
Intervention: HD including a single bout of hybrid intradialytic exercise
Number of subjects: 21
Study 34100215 — intervention group
Group type: COMPARATOR
Intervention: Standard HD
Number of subjects: 21
Study 34543581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 681
Study 34543581 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 681
Study 36228310 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day (Group 1)
Number of subjects: 90
Study 36228310 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day (Group 2)
Number of subjects: 90
Study 36228310 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/week (Group 3)
Number of subjects: 90
Study 36228310 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 90
Study 33988093 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative platelet-rich plasma intervention
Number of subjects: 56
Study 33988093 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 35533500 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light chain protein (NfL) levels on day one
Number of subjects: 0
Study 35533500 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NfL levels on day one
Number of subjects: 0
Study 35533500 — intervention group
Group type: EXPERIMENTAL
Intervention: Day one NfL levels
Number of subjects: 0
Study 33045216 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% ophthalmic solution
Number of subjects: 120
Study 33045216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33781066 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine (Septodont, Saint Maur des Fossés, France)
Number of subjects: 70
Study 33781066 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (Rootdent MTA, TehnoDent, Russia)
Number of subjects: 70
Study 33781066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX GP (GC Corporation, Tokyo, Japan)
Number of subjects: 70